WeFace
ActiveSummary
WeFace has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€8,881) and a net result of -€5,804. Its solvency ranks better than 5% of 20,612 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Overview
- Equity
- -€8,881
- Loss
- -€5,804
Why 52raises riskCapped at 59: negative equity1 change of registered office in 24 monthsNegative equity -€8,881lowers riskSector: Human health activities (NACE 86)Size: total assets €7,381Show the evidence
Checked score
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 1% on solvency, 8% on liquidity, 1% on profitability and 1% on growth.
The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 2 accounts on average 23 days after the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
- Annual accounts filedfinancial year 2025 · micro…
- Registered officeRegistered-office move
- Annual accounts filedfinancial year 2024 · micro…
Financials · financial year 2025, micro format
2025 annual accounts filed late (17 days) Filed on 17 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00402202.
2024 to 2025, 2 financial years
The operating result stays negative: a loss of €5,804 in 2025 against €3,177 in 2024; the loss grows.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital.
Peer companies
Historical observationOf the 1,322 companies that looked in July 2024 the way this one looks now, 4.2% went bankrupt within 24 months and 90.2% are still going.
- Micro
- under 2 years old
- negative equity
- a loss of 10% of the balance sheet or more
For this company itself Checked computes a lower bankruptcy probability: 0.4% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 1,322 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €278 | - |
| Gross operating margin9900 | -€3,177 | -€5,526 | ▼ 73.9% |
| Operating profit (loss)9901 | -€3,177 | -€5,804 | ▼ 82.7% |
| Financial charges65/66B | - | €0 | - |
| Recurring financial charges65 | - | €0 | - |
| Profit (loss) for the period before taxes9903 | -€3,177 | -€5,804 | ▼ 82.7% |
| Profit (loss) for the period9904 | -€3,177 | -€5,804 | ▼ 82.7% |
| Profit (loss) for the period to be appropriated9905 | -€3,177 | -€5,804 | ▼ 82.7% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €1,613 | €7,381 | ▲ 358% |
| Fixed assets21/28 | - | €1,521 | - |
| Tangible fixed assets22/27 | - | €1,521 | - |
| Furniture and vehicles24 | - | €1,521 | - |
| Current assets29/58 | €1,613 | €5,859 | ▲ 263% |
| Amounts receivable within one year40/41 | - | €75 | - |
| Trade receivables40 | - | €75 | - |
| Cash at bank and in hand54/58 | €100 | €2,116 | ▲ 21× |
| Deferred charges and accrued income490/1 | €1,513 | €3,668 | ▲ 142% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €1,613 | €7,381 | ▲ 358% |
| Equity10/15 | -€3,077 | -€8,881 | ▼ 189% |
| Contributions10/11 | €100 | €100 | = |
| Profit (loss) carried forward14 | -€3,177 | -€8,981 | ▼ 183% |
| Amounts payable17/49 | €4,691 | €16,262 | ▲ 247% |
| Amounts payable within one year42/48 | €4,691 | €16,262 | ▲ 247% |
| Trade debts44 | €4,691 | - | - |
| Suppliers440/4 | €4,691 | - | - |
| Taxes, remuneration and social security45 | - | €481 | - |
| Taxes450/3 | - | €481 | - |
| Other amounts payable47/48 | - | €15,781 | - |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€3,177 | -€5,804 | ▼ 82.7% |
| + Depreciation and write-downs630 | - | €278 | - |
| Operating cash flow (approximation) | -€3,177 | -€5,526 | ▼ 73.9% |
| Change in cash | - | €2,016 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (2)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 17-08-2026 | 2026-00402202 |
| 31-12-2024 | micro format | 29-08-2025 | 2025-00458302 |
Similar companies · same sector and region
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Mandate history
- Board
| Name | Functions and periods |
|---|---|
| VAN BOGAERT Wendy Anne Céline Marie |
|
Owners and capital
Capital and shareholders
- VAN BOGAERT Wendy Anne Céline Marie sole founder · 100% at incorporation
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 17-12-2024 Incorporation · €100 · 100 shares
Group and network
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
History
Acts, filings and financial milestones
13-08
Gazette deed
Registered officeRegistered-office move2 facts ▸
- Board meeting, 22-07-2026
- Registered-office move, Belzeelsestraat 34 te 9940 Evergem
17-12
Gazette deed
IncorporationAppointment: VAN BOGAERT Wendy Anne Céline Marie (director) · Founder · Founding capital8 facts ▸
- Incorporation, 12-12-2024
- Founder, VAN BOGAERT Wendy Anne Céline Marie (oprichter verschijner)
- Founding capital, €100
- Bank account, “Bank Van Breda, in dossier” (deed in Dutch)
- Declaration, “volledige storting inbreng” (deed in Dutch)
- Registered office clause, “J. Deschuyffeleerdreef 49,1780 Wemmel” (deed in Dutch)
- Director appointment, VAN BOGAERT Wendy Anne Céline Marie (director (not named in the articles))
- Other provision, “bestuursverbod, oprichter” (deed in Dutch)
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 26 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 44302E1627/00D000 | Flanders | 4,341 m² | 1 · 330 m² | 9.4 m · 2 |
How the parcels are linked
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “De uitoefening van de geneeskunde in naam en voor rekening van de vennootschap en meer specifiek de mond-, kaak- en aangezichtschirurgie…” (deed in Dutch)
4 activities (deed in Dutch)
- De uitoefening van de geneeskunde in naam en voor rekening van de vennootschap en meer specifiek de mond-, kaak- en aangezichtschirurgie, door haar aandeelhouders, zijnde uitsluitend artsen die op de lijst van de Orde der Artsen ingeschreven zijn en die hun volledige medische activiteit in de vennootschap uitoefenen
- Alle materiële voorwaarden te scheppen met het oog op het verstrekken van bedoelde geneeskundige zorgen. Zij kan onder meer geneeskundige apparatuur aanschaffen dienstig voor het voorwerp, ondergeschikt en paramedisch personeel aanwerven die de aandeelhouders in de uitoefening van hun beroep bijstaan
- Het bevorderen en verwezenlijken van medische studie, onder meer door bijwonen van colloquia en administratie
- Het occasioneel verstrekken van onderwijs gerelateerd aan voormelde specialisme, het geven van lezingen, het schrijven en laten publiceren van artikels en boeken
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- WeFace
- Legal form clauseThe legal form, such as BV, NV or CV, which decides which company-law rules apply.
- “Besloten professionele vennootschap” (deed in Dutch)
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, vrijwaring van de patiëntenbelangen” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meer bestuurders,natuurlijke personen, onbepaalde duur bij gebrek aan bepaling” (deed in Dutch)“14.1 Bevoegdheden, enkel niet-medische aangelegenheden” (deed in Dutch)
- Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
- One provision in the deed
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Monday of June at 18:00